The femtech sector continues to demonstrate strong investment momentum, with venture capital funding totaling $5.4 billion across more than 1,000 deals since 2020, according to Pitchbook’s Femtech VC Market Snapshot.

While deal counts have declined from a peak of 284 in 2021, funding levels have remained resilient. In 2024, femtech VC investment reached $1.2 billion—marking a 20% year-over-year increase—driven by a particularly strong Q3, which saw $0.5 billion in deal value. Notable 2024 investments include Flo Health’s $200 million Series C, Maven’s $150 million Series F, and Comanche Biopharma’s $90 million Series B.

Period tracking and virtual fertility platforms have emerged as top funding categories, securing $256 million and $165 million, respectively, over the past year. Despite funding growth, femtech exits have lagged behind, reflecting broader healthtech trends. After peaking at $2.3 billion in exit value in 2021, driven by Organon’s $955 million acquisition of Forendo Pharma, exit activity slowed significantly in 2022 and 2023. However, 2024 saw a resurgence with $0.8 billion in exit value, led by Hologic’s $350 million acquisition of Gynesonics and Compass Diversified’s $380 million buyout of The Honey Pot.

The sector’s IPO landscape remains quiet, but the presence of unicorns like Flo Health ($1.2 billion valuation) and Maven ($1.8 billion valuation) suggests that public market debuts may be on the horizon. Kindbody, Comanche Biopharma, and Elvie also show strong IPO potential, with implied probabilities exceeding 74%, according to PitchBook. As innovation in digital health and wearables accelerates—particularly with smart rings enhancing menstrual tracking and fertility insights—femtech is poised for continued expansion. With shifting social attitudes and increased investor interest, the sector remains a compelling space for growth and impact.